Contents of this document
Earnings presentation materialsFiscal year ending March 2026, third quarter2 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥207 million
Operating profit-771 Operating loss百万円
Ordinary income-734 Ordinary loss百万円
Net income-732 親会社株主に帰属する四半期純損失百万円
Selling, general and administrative expenses¥897 million
Full-year earnings forecast
Net Sales
¥212 million
Operating loss
¥-1,024 million
Ordinary loss
¥-981 million
Net loss attributable to owners of the parent
¥-983 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- 売上高増加（CDMO事業）¥180 million
- 売上原価増加（CDMO事業）¥75 million
- Increase in SG&A¥311 million
- Research and Development Costs Increased¥182 million
- Increase in share-based compensation expense¥74 million
- Increase in non-operating income¥25 million
- Decrease in non-operating expenses¥-56 million
New initiatives
- iPS心筋シートの製造販売承認申請・GCTP適合性調査対応
- スタンフォード大学との共同研究継続と米国治験申請準備
- 朝日インテックとのカテーテル共同研究開発継続
- 中之島クロスへの設備投資
- 心筋シート海外展開に向けたMOU締結の検討
- CIRMグラント二次審査対応
- 細胞大量培養システムの技術開発
| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | Fiscal year ending March 2026, third quarter |
| Net Sales | ¥207 million |
| Operating profit | -771 営業損失（百万円） |
| Ordinary income | -734 経常損失（百万円） |
| Net income | -732 親会社株主に帰属する四半期純損失（百万円） |
| Selling, general and administrative expenses | ¥897 million |
| Full-year earnings forecast | Net Sales ¥212 million / Operating loss ¥-1,024 million / Ordinary loss ¥-981 million / Net loss attributable to owners of the parent ¥-983 million |
| Breakdown of Factors Affecting the Change | Factors 売上高増加（CDMO事業） / Amount ¥180 million, Factors 売上原価増加（CDMO事業） / Amount ¥75 million, Factors Increase in SG&A / Amount ¥311 million, Factors Research and Development Costs Increased / Amount ¥182 million, Factors Increase in share-based compensation expense / Amount ¥74 million, Factors Increase in non-operating income / Amount ¥25 million, Factors Decrease in non-operating expenses / Amount ¥-56 million |
| New initiatives | iPS心筋シートの製造販売承認申請・GCTP適合性調査対応, スタンフォード大学との共同研究継続と米国治験申請準備, 朝日インテックとのカテーテル共同研究開発継続, 中之島クロスへの設備投資, 心筋シート海外展開に向けたMOU締結の検討, CIRMグラント二次審査対応, 細胞大量培養システムの技術開発 |
Items this document does not state (21)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planSegment resultsKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.